Kopran Limited (IN:KOPRAN)
:KOPRAN
Want to see IN:KOPRAN full AI Analyst Report?
KOPRAN Stock Chart & Stats
₹152.20
-₹3.64(-1.71%)
At close: 4:00 PM EST
₹152.20
-₹3.64(-1.71%)
Day’s Range― - ―
52-Week Range₹107.00 - ₹212.50
Previous CloseN/A
Volume53.95K
Average Volume (3M)13.07K
Market Cap
₹7.51B
Enterprise Value₹9.00B
Total Cash (Recent Filing)₹372.08M
Total Debt (Recent Filing)₹1.57B
Price to Earnings (P/E)19.4
Beta1.61
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.96%
Share Statistics
EPS (TTM)1.93
Shares Outstanding48,285,606
10 Day Avg. Volume27,236
30 Day Avg. Volume13,071
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)1.74
Price to Sales (P/S)1.44
P/FCF Ratio-67.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong CapitalizationA high equity ratio (61.4%) and low debt-to-equity (0.29) indicate durable capitalization. This conservative leverage profile supports regulatory compliance investment, capacity expansion, and buffers against sector cyclicality, reducing refinancing risk and preserving strategic optionality over months.
Operational EfficiencyA marked improvement in EBIT margin to 26.1% and a 35.7% gross margin reflect sustained cost control and pricing power in manufacturing. Higher operating efficiency across APIs and formulations supports long-term margin sustainability and cash generation if maintained across product mix.
Integrated Pharma ModelVertical presence across APIs and finished dosage formulations and exposure to domestic plus export markets provides durable diversification. Integration reduces input risk, captures manufacturing and formulation margins, and creates multiple revenue levers for steadier medium-term growth.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow, with FCF-to-net-income at -0.35, signals weak cash conversion despite positive operating cash flow. Heavy capex or working capital needs constrain internal funding for growth, limit deleveraging or shareholder returns, and increase reliance on external financing.
Weaker Net ProfitabilityA drop in net margin from 8.4% to 6.1% indicates pressure below the operating line—tax, interest, or non-operating items reducing bottom-line returns. Over months this compresses retained earnings, limits reinvestment capacity, and reduces resilience to raw-material or pricing shocks.
Earnings VolatilityA steep EPS decline (~-65%) points to volatile profitability or one-off impacts that impair earnings quality. Such volatility hampers long-term planning, weakens investor confidence, and may constrain capital allocation choices for R&D, capacity, or dividends until earnings stabilize.
Kopran Limited News
KOPRAN FAQ
What was Kopran Limited’s price range in the past 12 months?
Kopran Limited lowest stock price was ₹107.00 and its highest was ₹212.50 in the past 12 months.
What is Kopran Limited’s market cap?
Kopran Limited’s market cap is ₹7.51B.
When is Kopran Limited’s upcoming earnings report date?
Kopran Limited’s upcoming earnings report date is May 21, 2026 which is in 23 days.
How were Kopran Limited’s earnings last quarter?
Kopran Limited released its earnings results on Jan 22, 2026. The company reported ₹1.934 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.934.
Is Kopran Limited overvalued?
According to Wall Street analysts Kopran Limited’s price is currently Overvalued.
Does Kopran Limited pay dividends?
Kopran Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of 1.96%. See more information on Kopran Limited dividends here
What is Kopran Limited’s EPS estimate?
Kopran Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kopran Limited have?
Kopran Limited has 48,285,606 shares outstanding.
What happened to Kopran Limited’s price movement after its last earnings report?
Kopran Limited reported an EPS of ₹1.934 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.111%.
Which hedge fund is a major shareholder of Kopran Limited?
Currently, no hedge funds are holding shares in IN:KOPRAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kopran Limited
Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, dry powder, suspension, and injectables. It also provides active pharmaceutical ingredients in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. The company was incorporated in 1958 and is headquartered in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Sanofi India Limited
―
SMS Pharmaceuticals Limited
―